Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023 Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filing Alzheimer’s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April […]

LONDON, UK and NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). However, when a company is bringing a drug to trial in near-record […]

HOUSTON, TX / ACCESSWIRE / April 19, 2023 / Viking Energy Group, Inc. (OTCQB:VKIN) (“Viking“) and Camber Energy, Inc. (NYSE American:CEI) (“Camber“) and are pleased to announce that on April 18, 2023, they entered into an amendment (the “Amendment“) to the Amended and Restated Agreement and Plan of Merger, dated as of February 15, 2021, regarding the full […]

SHARON, Pa., April 19, 2023–(BUSINESS WIRE)–Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or the “Company”), a digital infrastructure provider, announces today that it has signed and closed a binding sale agreement for Mawson’s greenfield sites in Midland, TX, effective April 18, 2023. The sale price was $8.5m in cash and stablecoins. The transaction involved the […]

Investment Income from Lending Operations Increases 58% Shareholder Equity Increases 36.7% Mustang Acquisition on Pace to Close in 2023 Second Half MINNEAPOLIS, MN / ACCESSWIRE / April 17, 2023 / Mill City Ventures III, Ltd. (NASDAQ:MCVT) (Mill City or the “Company”) a non-bank lender and specialty finance company, today announced financial results for the three-month and full year-month […]

CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and […]

ORLANDO, FL / ACCESSWIRE / April 18, 2023 / Laser Photonics Corporation (NASDAQ:LASE) (“LPC”), a leading global developer of industrial cleantech laser systems for laser cleaning and other materials applications, today announced it received an order from Gateway Clipper, an operator of sightseeing and dinner cruises on Pittsburgh’s Three Rivers. Peter Evans, president of Laser Photonics, commented: “Gateway […]

DETROIT, April 18, 2023 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces today the demonstration of AI generated content with AI narration capabilities on its recently launched Version 6.0 platform, complementing its recent GPT-4 integration. The capabilities, demonstrated in Amesite’s free-to-the-public […]

SHELTON, CT / ACCESSWIRE / April 17, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”). Karveer has already […]